Upcoming Events Webinars

with TRI

Embark on a journey to unleash the full capabilities of Risk-Based Quality Management (RBQM) by joining TRI at forthcoming industry gatherings and participating in our specialized webinars led by seasoned experts.


    TESTIMONIALS

    RBQM Success Stories

    Hear directly from our partners about how we've helped them.

    Peter Benton President & CEO, Worldwide

    Worldwide’s RBQM team is one of the most experienced CRO teams in the industry. This, coupled with TRI’s best-in-class technology, ensures we can proactively identify and manage risks, meaning improved quality and patient safety, and, in turn, provide a better experience for sponsors and patients.

    Jeff Smith Former CEO, Alimentiv

    What truly set TriTrials apart from other vendors was their unparalleled commitment to a quality deliverable helping us effectively apply a novel approach to our operations. They achieved a deep understanding of our objectives by partnering with us on a rigorous change management process which culminated in a shared vision for the integration of their risk assessment and central monitoring solution.

    Amandeep Sonik Senior Director, RBQM, Worldwide

    The Worldwide Clinical Trials team is pleased with our continued partnership with TRI and we are excited about the milestone of having 150 clinical trials in TRI's Risk-Based Quality Management platform. This is a key benefit for our customers as it improves data quality, trial efficiency, and patient safety.

    Kelly Parish Holladay AD, RBQM, Worldwide

    It has been such a wonderful ride with our TRI partners over the last few years developing our RBQM strategy with our Sponsors and Worldwide Clinical Trials Teams! We love working with everyone at TRI and look forward to bigger and better things to come!

    RBQM NEWS

    Clinical trial quality news and views

    Subscribe to get the latest RBQM insights sent to your mailbox.

    When RBQM Pilots Stall

    When RBQM Pilots Stall

    Partial RBQM implementation is a structural weakness that exposes sponsors to risk and regulatory scrutiny.

    The Non-Negotiable Standard in Clinical Trials

    The Non-Negotiable Standard in Clinical Trials

    In 2026, global regulators will require RBQM in every stage of clinical trials

    How Much Change Is Enough to Be Compliant with ICH E6(R3)?

    How Much Change Is Enough to Be Compliant with ICH E6(R3)?

    Learn how to make the right changes, not just more changes, to meet compliance confidently.